You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 160 No. 6, March 27, 2000 TABLE OF CONTENTS
  Archives
  •  Online Features
  Original Investigation
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on ISI (56)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal

Regional and Racial Differences in Response to Antihypertensive Medication Use in a Randomized Controlled Trial of Men With Hypertension in the United States

William C. Cushman, MD; Domenic J. Reda, MS; H. Mitchell Perry, Jr, MD; David Williams, MS; Mazen Abdellatif, MS; Barry J. Materson, MD; for the Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents

Arch Intern Med. 2000;160:825-831.

Background  Stroke incidence and mortality rates are higher in the southeastern region of the United States, which is called the "Stroke Belt." We compared the response to antihypertensive medication use in patients from different US regions.

Methods  The short-term and 1-year efficacy of the antihypertensive medications hydrochlorothiazide, atenolol, diltiazem hydrochloride (sustained release), captopril, prazosin hydrochloride, and clonidine was compared by US region in a randomized controlled trial of 1105 men with hypertension from 15 US Veterans Affairs medical centers.

Results  Compared with patients outside the Stroke Belt, patients inside the Stroke Belt achieved significantly lower treatment success rates of diastolic blood pressure control at 1 year with hydrochlorothiazide (63% vs 41%), atenolol (62% vs 46%), captopril (60% vs 30%), and clonidine (69% vs 43%); there were no differences in treatment success rates with diltiazem (70% vs 71%) or prazosin (54% vs 53%). When controlling for race, patients inside the Stroke Belt had significantly lower treatment success rates with hydrochlorothiazide (P = .003) and clonidine (P = .003), and the lower success rate with atenolol approached significance (P = .15). Regardless of region, blacks were less likely than whites to achieve treatment success with atenolol (P = .02) or prazosin (P = .03) and more likely with diltiazem (P = .05). There was a trend for blacks residing inside the Stroke Belt to have a lower treatment success rate than other race-region groups when treated with captopril (P = .07). Many regional and racial differences in diet, lifestyle, and other characteristics were observed. After adjustment for these characteristics by regression analysis, the effect of residing inside the Stroke Belt remained for captopril (P = .01) and clonidine (P = .01) and approached significance for hydrochlorothiazide (P = .10).

Conclusions  Hypertension in patients residing inside the Stroke Belt responded less to the use of several antihypertensive medications and important differences were shown in a number of characteristics that may affect the control of blood pressure, compared with patients residing outside the Stroke Belt.


From the Cooperative Studies Program, Department of Veterans Affairs Research and Development Service, Veterans Affairs Medical Center, Memphis, Tenn. A complete list of the members of the Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents has been published previously (N Engl J Med. 1993;328:914-921).



THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Trends and Cardiovascular Mortality Effects of State-Level Blood Pressure and Uncontrolled Hypertension in the United States
Ezzati et al.
Circulation 2008;117:905-914.
ABSTRACT | FULL TEXT  

2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)
Authors/Task Force Members: et al.
Eur Heart J 2007;0:ehm236v1-75.
FULL TEXT  

Factors Associated With Geographic Variations in Stroke Incidence Among Older Populations in Four US Communities
El-Saed et al.
Stroke 2006;37:1980-1985.
ABSTRACT | FULL TEXT  

Managing hypertension in patients with type 2 diabetes mellitus.
Dobesh
Am J Health Syst Pharm 2006;63:1140-1149.
ABSTRACT | FULL TEXT  

Comparison of Monotherapy with Irbesartan 150 mg or Amlodipine 5 mg for Treatment of Mild-to-Moderate Hypertension
Neutel et al.
Journal of Renin-Angiotensin-Aldosterone System 2005;6:84-89.
ABSTRACT  

Outcomes in Hypertensive Black and Nonblack Patients Treated With Chlorthalidone, Amlodipine, and Lisinopril
Wright et al.
JAMA 2005;293:1595-1608.
ABSTRACT | FULL TEXT  

Variability in Response to Antihypertensive Drug Treatment
Materson
Hypertension 2004;43:1166-1167.
FULL TEXT  

Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
Chobanian et al.
Hypertension 2003;42:1206-1252.
ABSTRACT | FULL TEXT  

Angiotensin-Converting-Enzyme Inhibitors and Diuretics for Hypertension
Pickering et al.
NEJM 2003;349:90-93.
FULL TEXT  

`Size is not everything`: the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT): The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomised to angiotensin-converting enzyme inhibitor or calcium channel blocker versus diuretic. The Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT)
Mcinnes
British Journal of Diabetes & Vascular Disease 2003;3:263-267.
ABSTRACT  

Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): Practical Implications
Oparil
Hypertension 2003;41:1006-1009.
FULL TEXT  

Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients
Flack et al.
J Am Coll Cardiol 2003;41:1148-1155.
ABSTRACT | FULL TEXT  

Management of High Blood Pressure in African Americans: Consensus Statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks
Douglas et al.
Arch Intern Med 2003;163:525-541.
FULL TEXT  

Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
The ALLHAT Officers and Coordinators for the ALLHA
JAMA 2002;288:2981-2997.
ABSTRACT | FULL TEXT  

Stroke Risk Factor Profiles in African American Women: An Interim Report From the African-American Antiplatelet Stroke Prevention Study
Worrall et al.
Stroke 2002;33:913-919.
ABSTRACT | FULL TEXT  

Associations Between Birth Weight and Antihypertensive Medication in Black and White Medicaid Recipients
Lackland et al.
Hypertension 2002;39:179-183.
ABSTRACT | FULL TEXT  

Hemodynamic effects of lipids in humans
Stojiljkovic et al.
Am. J. Physiol. Regul. Integr. Comp. Physiol. 2001;280:R1674-R1679.
ABSTRACT | FULL TEXT  

Racial Differences in Mortality Among Men Hospitalized in the Veterans Affairs Health Care System
Jha et al.
JAMA 2001;285:297-303.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2000 American Medical Association. All Rights Reserved.